A dietary supplement containing OptiBiotix Health plc’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain has launched in the US.
Seed Health struck a deal with AIM-quoted Opti to produce, market and commercialise products containing the LPLDL strain in May.
READ: OptiBiotix inks US deal for breakthrough cholesterol strain
The US supplements maker has now launched its Daily Symbiotic capsules which can be bought directly through its website.
It is a significant achievement for OptiBiotix, marking its entry into one of the largest and fastest-growing probiotic markets in the world and one which is expected to be worth more than US$3bn by 2021.
Boss wants more product launches
“We are excited to see the launch of products containing our cholesterol reducing LPLDL strain in the USA, the world's largest and fastest growing probiotic market,” said Opti’s chief executive Stephen O’Hara.
“The launch with Seed substantiates the science behind LPLDL and helps build the LPLDL brand in the consumer healthcare market around the world.”
He added: “We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of products in the USA and around the world.”